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Abstract
Sexual dysfunction is a common cause of selective serotonin reuptake inhibitor (SSRI) 
withdrawal. Various studies indicate that decreased oxytocin is involved as a mechanism of 
delayed ejaculation induced by SSRIs. The aim of the present pilot study was to evaluate and 
compare sexual dysfunction and oxytocin levels in women being treated with either fluoxetine 
or citalopram. Thirty-nine women with the diagnosis of major depressive disorder were 
enrolled in the study. A baseline blood sample was collected and each participant was given 
either fluoxetine 20 mg/d or citalopram 20 mg/d. After 1 month, a second blood sample was 
collected and sexual dysfunction was evaluated via the Female Sexual Function Index (FSFI) 
questionnaire. Twenty-three women completed the study (12 and 11 in the fluoxetine and 
citalopram groups, respectively). After 1 month, the FSFI scores were 22.8 ± 7.8 and 22.5 ± 4.8 
in the fluoxetine and citalopram groups, respectively. The oxytocin levels were 187.8 ± 38.8 
pg/mL and 214.6 ± 23.1 pg/mL in the fluoxetine and citalopram groups, respectively. Statistical 
analysis did not reveal any difference in the FSFI score between the two groups after 1 month 
(p = 0.89). However, the oxytocin levels were significantly lower in the fluoxetine group than 
in the citalopram group (p = 0.05). We also observed a positive relationship between the FSFI 
score and oxytocin level at 1 month after starting fluoxetine or citalopram (r = 0.43, p = 0.04).A 
positive relationship between the oxytocin level and FSFI score supports the hypothesis that the 
oxytocin level plays a role in sexual dysfunction induced by SSRIs.
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Introduction
Today, selective serotonin reuptake inhibitors 
(SSRIs) are the first choice for pharmacotherapy 
of depression. The efficacy of SSRIs is superior 
to that of placebo and comparable to that of other 
classes of antidepressants in treating patients with 
major depression (1). Sexual dysfunction is a 
common side effect of SSRIs and may be a reason 
for the discontinuation of SSRIs among those 
who use them permanently. SSRIs can reduce 
libido in women and men, cause anorgasmia 
in women, and increase time to ejaculation in 
men (2-4). The reported incidence of sexual 
dysfunction varies widely because of differences 
in the methodology between studies, and the 
incidence of SSRI-induced sexual dysfunction 
ranges from approximately 15% to 80% of 
patients (5-7). Other antidepressant medications 
can cause sexual dysfunction; however, sexual 
dysfunction is more often secondary to SSRIs 
than to other antidepressants (6).
The exact mechanism of sexual disorders 
induced by SSRIs is unknown; however, they 
can induce sexual dysfunction via interactions 
with different hormones and neurotransmitters, 
including dopamine, prolactin, acetylcholine, 
and nitric oxide. Dopamine neurotransmission 
has consistently been shown to be involved in 
sexual arousal. In animal models, dopamine 
agonists decrease the ejaculatory threshold, 
whereas the destruction of dopaminergic 
neurons is associated with prolonged ejaculatory 
latency (8). Elevated prolactin concentrations 
are associated with a marked inhibition of 
sexual desire and performance (8). SSRIs may 
be the most common cause of drug-induced 
hyperprolactinemia (9). The findings are 
consistent with the hypothesis that cholinergic 
neurotransmission has a modulating effect when 
other neurotransmitter systems are involved (8). 
Nitric oxide is critical in the signal transduction 
pathway mediating the penile vascular changes 
required for erection (10).
Recently, the clinical relevance of oxytocin 
in SSRI-induced sexual dysfunction has been 
raised. It has been hypothesized that oxytocin 
should be able to positively influence the 
parameters of sexual function and couple 
interactions. Oxytocin is clearly involved in 
human reproduction and serves an important 
role in sexual arousal. The presence of oxytocin 
receptors on multiple organs such as female 
genital organs, suggests a possible preparatory 
role of oxytocin for the later and final phase 
of the copulatory process, such as ejaculation 
and orgasm, preparing all necessary muscular 
contraction and lubrication effects (11). Infusion 
of oxytocin antagonists into cranial vertebrae in 
rats had an inhibitory effect on female sexual 
behavior (12). In a recent trial, the effect of 
intranasal administration of oxytocin was 
evaluated in 29 healthy heterosexual couples. It 
was reported that women felt more relaxed and 
subgroups indicated a greater ability to share 
sexual desires or to empathize with their partners 
(13).
It seems that postsynaptic receptors of 
5-hyroxytryptamine1A (5HT1A) have a 
potential role in oxytocin release. The increased 
serotonin concentrations induce oxytocin 
release via activation of 5HT1A receptors and 
this might compensate for the inhibitory effect 
of serotonin on sexual function (14). In animal 
studies, an inverse effect on oxytocin levels has 
been reported between fluoxetine and citalopram 
administration (15, 16). As a difference in 
oxytocin level may be part of the sexual 
dysfunction induced by SSRIs, we designed 
a clinical study to evaluate sexual dysfunction 
and oxytocin levels among women treated with 
either fluoxetine or citalopram.
Methods
Study design & Patient recruitment
An open label clinical trial study, registered 
in Australian and New Zealand Registry of 
Clinical Trials (ACTRN12614000869673), was 
performed from January 2014 until January 
2015 in the psychiatric clinic of Taleghani 
Hospital, affiliated to Shahid Beheshti 
University of Medical Sciences, Tehran, Iran. 
Ethical committee approval was obtained from 
Shahid Beheshti University of Medical Sciences 
before starting the study as per the provision of 
the Helsinki declaration (2000) and all patients 
were given their informed consent forms. The 
inclusion criteria were as follows: (1) women 
aged between 18 and 45 years with major 
depression diagnosed by an expert psychiatric 
physician based on the DMS-IV, who were 
candidates for administration of either fluoxetine 
or citalopram and (2) women who had no history 
of sexual dysfunction. Patients were excluded if 
they fulfilled any of the following criteria: (1) 
menopause, (2) pregnancy, (3) lactation, (4) 
history of any pituitary disorders, (5) receiving 
any medications that induce sexual dysfunction 
during the study or within the preceding 2 
months, (6) receiving any medications, which 
can cause drug interactions with SSRIs during 
the study or within the preceding 2 months and 
(7) addiction to any agents.
Eligible patients who met the inclusion 
criteria were randomly allocated into either the 
fluoxetine 20 mg/day or the citalopram 20 mg/
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day group. If they met none of the exclusion 
criteria, the physiatrist instructed the patients to 
take their drugs for at least 1 month. Adherence 
to treatment was determined by counting the 
tablets left in the container at the end of 1 month. 
Assessment of sexual dysfunction 
The Female Sexual Function Index (FSFI) 
questionnaire was used to measure the women’s 
sexual functioning on the basis of self-reports 
before and 1 month after the start of treatment. 
This questionnaire contains 19 items, covering 
female sexual arousal disorder (FSAD), 
hypoactive sexual desire disorder (HSDD), 
female sexual orgasm disorder (FSOD), 
dyspareunia/vaginismus (pain), and multiple 
sexual dysfunctions. Then, all scores of 6 
items are added to create a total score for each 
patient. The total score ranges from a minimum 
score of 6 to a high score of 36 (17). The FSFI 
questionnaire has been previously validated by 
Mohammadi et al. among Iranian women to 
assess sexual dysfunction (18). 
Measurement of oxytocin level
Venous blood samples were collected from all 
women who met the inclusion criteria at baseline 
(before taking citalopram or fluoxetine), and 1 
month after treatment. Samples were collected 
and centrifuged for 10 min within a few hours 
of sampling. Plasma was removed and frozen at 
−70 °C until completion of the study. All samples 
were measured in a single assay. Plasma oxytocin 
levels were determined by radioimmunoassay 
kit (Phoenix Pharmaceuticals, Inc., USA). 
The sensitivity was 0.6 pg/mL, and the intra- 
and inter-assay coefficients of variation were 
7% and 15%, respectively.
Statistical analyses
The data were analyzed using SPSS version 
20 for windows (SPSS Inc., Chicago, IL, USA) 
software. Mean (SD) and median (IQ) of 
continuous variables were compared between two 
groups using an independent sample t-test (for 
normally distributed data) and a Mann–Whitney 
U test (for non-normally distributed data), 
respectively. Pearson’s correlation was used to 
show the strength and direction of a relationship 
between two variables when at least one variable 
was normally distributed. If the assumption 
of normality was not met, Spearman’s rank 
correlation was used. p ≤ 0.05 was considered to 
indicate statistical significance.
Results
Characteristic of the participants
During the study period, 39 women were 
screened initially and finally, 23 women with 
an average age of 29.0 ± 7.4 years met the 
inclusion criteria and were admitted to the study 
(Figure 1).Characteristics of the studied patients 
are shown in Table 1. Among them, 12 patients 
received fluoxetine and 11 received citalopram. 
All patients who entered completed the study 
until the end. 
The average ages of the study participants are 
Table 1. comparing of age, BMI, education level and FSFI at baseline and after 1 month between two groups
Fluoxetine group (n = 12) Citalopram group (n = 11) p value
Mean age (± SD) 30.4 + 7.6 27.8+ 7.3 0.41
BMI (±SD) 22.0 ± 2.2 22.7 ± 2.1 0.49
Education level
Under Diploma  1 2
0.77Diploma 7 6
Above Diploma 4 3
Baseline FSFI score ( ± SD) 30.0 ± 2.0 32.0± 2.0 0.89
FSFI score after 1 month ( ± SD) 22.8 ± 7.8 22.5 ± 4.8 0.89
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shown in table 1 and statistical analysis did not 
detect a significant difference between the two 
groups (p = 0.41).
FSFI scores before and after receiving 
medications
The mean FSFI score of all 23 patients was 
31.0 ± 2.0 before starting the medications. The 
FSFI scores in the two groups are shown in 
table 1. Statistical analysis did not detect any 
difference regarding baseline FSFI in the two 
groups (p = 0.89). We found a total FSFI score 
of 22.6 ± 6.4 after 1 month of drug treatment in 
all women. Average FSFI scores in fluoxetine 
and citalopram groups are shown in table 1. 
Statistical analysis did not detect significant 
differences between FSFI scores of patients 
who received fluoxetine and those receiving 
citalopram after 1 month (p = 0.89).
Plasma levels of oxytocin before and after 
receiving medications
Plasma levels of oxytocin before and after 
starting either fluoxetine or citalopram were 
determined and are presented in Figure 2. No 
significant difference was detected in oxytocin 
concentration between the two groups at baseline 
(p = 0.71). Mean oxytocin level was higher in the 
citalopram group (214.6 ± 23.1 pg/mL) than in 
the fluoxetine group (187.8 ± 38.8 pg/mL) after 
1 month. A statistically significant difference in 
the mean oxytocin level was observed after 1 
month between the groups (p = 0.05).
Correlation between FSFI score and oxytocin 
level after 1 month
Figure 3 shows the relationship between FSFI 
score and oxytocin level in the study participants 
1 month after starting the medications. There 
Figure 1. Fellow of the study  
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was a meaningful correlation found between 
FSFI and oxytocin level (r = 0.43, p = 0.04). 
Otherwise, there appeared to be a modest 
correlation between FSFI score and oxytocin 
level in the study participants.
Discussion
Although there are controversies regarding the 
clinical role of oxytocin in sexual dysfunction, it 
has been mentioned as an interactive parameter 
of sexual dysfunction. Muin et al. have evaluated 
the use of intranasal oxytocin (32 IU) or 
placebo in women within 50 min before sexual 
intercourse. 
The primary outcome of their study was 
FSFI score and they concluded that following 
administration of oxytocin and placebo, 
the FSFI score increased by 26% and 31%, 
respectively, but no significant difference was 
found between the two groups (19). However, 
Behnia et al. evaluated the acute effects of 
intranasal oxytocin (24 IU) on sexual drive, 
arousal, orgasm, and refractory aspects of sexual 
behavior together with partner interactions. 
They reported that women felt more relaxed 
and subgroups indicated better abilities to share 
sexual desires or to empathize with their partners 
(13). Sexual dysfunction due to SSRIs appears 
to depend on not only on serotonin receptors but 
also on other mechanisms. Moreover, different 
hormones and neurotransmitters are involved in 
the development of this side effect (20). Ozsoy 
et al. have evaluated serum oxytocin levels in 40 
patients with depression before and after treatment 
with antidepressant drugs or electroconvulsive 
therapy. They reported that antidepressant 
treatments appeared to have no effect on serum 
oxytocin concentration. They did not indicate 
which type of antidepressant agents were taken 
by the evaluated patients (21). Keating et al. 
evaluated plasma oxytocin in patients diagnosed 
with major depressive disorders before and 
following treatment with SSRIs. They failed to 
detect a difference in oxytocin concentration 
before and after SSRI treatment, and there were 
no significant relationships between oxytocin 
and psychological symptom scores, before or 12 
weeks after treatment (22). They did not indicate 
which kind of SSRIs were used in the patients 
they evaluated.
Regarding the observation that the prevalence 
of sexual dysfunction is high among SSRI users, 
and that it is not exactly known how SSRIs impair 
sexual function, we designed a comparative study 
to measure oxytocin concentrations in women 
who received citalopram or fluoxetine after 1 
month. We choose these two SSRIs because, in 
animal studies, fluoxetine and citalopram have 
been reported to affect oxytocin levels in opposite 
ways (15, 16). De Jong et al. have concluded that 
if chronic treatment with citalopram increases 
oxytocinergic neurotransmission whereas 
chronic treatment with fluoxetine inhibits it; 
Figure 2. Oxytocin concentration before and after taking either fluoxetine or citalopram.
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this could underlie the difference in effect of 
these two SSRIs on ejaculatory latency (14). 
Regarding FSFI as a primary outcome of sexual 
dysfunction, we did not observe any difference 
in basal sexual function in our patients (p = 
0.89). Although a reduction in FSFI was seen 
in both groups after 1 month, no significant 
difference was detected between the two 
groups. A limitation in the number of evaluated 
patients may have prevented us from detecting 
a difference between the two groups, because 
there are some reports regarding the variability 
of sexual dysfunction associated with different 
SSRIs. For instance, a recent cross-sectional 
study among 100 patients attending a university 
or private psychiatric clinic reported sexual 
dysfunction in 100% of patients who received 
fluoxetine and 71.4% who took citalopram (23).
We tried to exclude all confounding factors, 
such as lactation and pregnancy, which may 
have altered oxytocin levels during the study. 
The pattern of oxytocin levels in the circulation 
was the same during both stages of the menstrual 
cycle. Also, there was no pulsatile pattern of 
oxytocin level in the blood of women in the 
basal state (24). In this study, oxytocin level did 
not differ between the two groups (p = 0.71) at 
baseline, but a meaningful decrease in oxytocin 
level and an increase in oxytocin level was 
detected in our patients in the fluoxetine and 
citalopram groups, respectively, after 1 month 
(p = 0.05). In agreement with our study, a study 
by Cantor et al. showed that administration 
of oxytocin may help to alleviate the sexual 
side effects of fluoxetine in rats (25). We also 
observed a positive relationship between FSFI 
score and oxytocin level 1 month after starting 
fluoxetine or citalopram (r = 0.43, p = 0.04). 
This means that sexual functioning in the study 
subjects may have been improved by increasing 
their oxytocin levels. Not only have sexual side 
effects of SSRIs been attributed to oxytocin but 
there is also some evidence regarding the role 
of oxytocin in the SSRI effect. Emilliano et al. 
reported that the therapeutic effects SSRIs on 
social affiliation and anxiety may be mediated in 
part by components of oxytocin (26). 
This is the first pilot clinical trial to study 
the effect of two different SSRIs (fluoxetine and 
citalopram) on oxytocin levels in women. We also 
noticed, for the first time, a correlation between 
FSFI (as an indicator of sexual dysfunction) and 
oxytocin. We were limited in both the sample 
size and duration of the study. The patient follow 
up was of limited duration; thus, the comparative 
effect of fluoxetine and citalopram on oxytocin 
over the long term is unknown. 
Conclusion
A positive relationship between the oxytocin 
level and FSFI score supports the hypothesis 
that the oxytocin level plays a role in sexual 
dysfunction induced by SSRIs.
Figure 3. Scatterplot of FSFI score and oxytocin level.
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